What We Saw in 2026?
The 3rd GLP-1 Summit was the essential global forum to master the next generation of therapeutics.
With the GLP-1 pipeline entering a fiercely competitive phase where differentiation is the sole commercial driver, this summit was your strategic mandate to push beyond monotherapy and secure your 2026 market position.
We dove deep into multi-agonist combinations, next-generation tolerability, adaptive clinical trial design, and the untapped potential in emerging indications, including neurodegenerative disease from industry giants including Eli Lilly, AstraZeneca and Sanofi.
Attendees didn’t miss the opportunity to forge crucial collaborations and be part of the solution defining the future of GLP-1 treatments.
Snapshot of the 2026 Speaker Faculty
Top Takeaways:
Unlocked the next generation of GLP-1 combinations and gained competitive intelligence on multi-agonist and combination therapies designed to enhance efficacy, minimize muscle loss, and improve body composition for superior patient outcomes
Discovered high-value indication expansion and explored the next frontier of GLP-1 development beyond obesity through exclusive data on clinical programs targeting liver, renal and cardiometabolic disorders alongside neurological diseases and women’s health conditions
Mastered alternative delivery and patient adherence through dedicated sessions focused on overcoming the challenges of administration through oral programs and less frequent dosing strategies for long-term patient success
Benchmarked against industry titans and innovators and heard directly from the companies leading the pipeline, including experts from Eli Lilly, Constructive Bio and Regeneron
Explore the 2026 Full Event Guide
- Analyze clinical strategies for reducing adverse GI effects and optimizing the side effect profile to improve patient comfort ensuring greater medication adherence
- Access advanced research and clinical insights on emerging multi-agonists (e.g., GLP-1/GCG/Amylin) and pharmacogenetics (PMX)
- Explore sessions dedicated to gaining the commercial and clinical blueprint for pioneering GLP-1 therapies in new frontiers
- Strategically apply collated insights from recent FDA-approved drugs and successful trial data
- Discover two focused, practical workshops that will provide actionable strategies on drug modelling and design
2026 Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.